These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28110992)

  • 1. Idarucizumab for the Reversal of Dabigatran.
    Gottlieb M; Khishfe B
    Ann Emerg Med; 2017 May; 69(5):554-558. PubMed ID: 28110992
    [No Abstract]   [Full Text] [Related]  

  • 2. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
    Lindeman E
    Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
    Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
    Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].
    Bereczki D; Szilágyi G; Kakuk I; Szakács Z; May Z
    Ideggyogy Sz; 2017 Sep; 70(9-10):349-353. PubMed ID: 29870627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series.
    Peacock WF; Grotta JC; Steiner T
    J Emerg Med; 2019 Dec; 57(6):e167-e173. PubMed ID: 31662218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
    Quintard H; Viard D; Drici MD; Ruetsch C; Samama CM; Ichai C
    Thromb Haemost; 2017 Jan; 117(1):196-197. PubMed ID: 27734073
    [No Abstract]   [Full Text] [Related]  

  • 13. Idarucizumab (Praxbind)--an antidote for dabigatran.
    Med Lett Drugs Ther; 2015 Nov; 57(1482):157-8. PubMed ID: 26583604
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
    Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
    Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
    van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
    Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarucizumab for dabigatran overdose in a child.
    Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
    Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
    Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
    Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarucizumab: The Antidote for Reversal of Dabigatran.
    Eikelboom JW; Quinlan DJ; van Ryn J; Weitz JI
    Circulation; 2015 Dec; 132(25):2412-22. PubMed ID: 26700008
    [No Abstract]   [Full Text] [Related]  

  • 19. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.
    Schulz JG; Kreps B
    J Neurol Sci; 2016 Nov; 370():44. PubMed ID: 27772783
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.